Skip to main content
Pharmadrug Inc. logo

Pharmadrug Inc. — Investor Relations & Filings

Ticker · PHRX ISIN · CA71716W2040 LEI · 529900PHQPAWL5ITEB39 CSE Manufacturing
Open in API
Filings indexed 475 across all filing types
Latest filing 2021-02-08 Board/Management Inform…
Country CA Canada
Listing CSE PHRX

About Pharmadrug Inc.

https://pharmadrug.ca/

Pharmadrug Inc. is a specialty pharmaceutical company focused on the research, development, and commercialization of controlled-substances and natural medicines. The company's primary focus areas include the clinical development of reformulated natural-based medicines aimed at treating unmet needs in oncology and infectious diseases. Additionally, Pharmadrug develops synthetic and biosynthetic formulations of existing drugs, specifically addressing opportunities related to the potential third wave of drug policy reform concerning controlled substances.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Board/Management Information Classification · 95% confidence The document is a press release announcing the appointment of Dr. Steven A. Barker to the scientific advisory board of PharmaDrug Inc. It focuses on the company's research and development initiatives in psychedelic pharmaceuticals, specifically DMT. There is no financial data, no regulatory filing references, no voting results, no management or board changes beyond this advisory appointment, and no mention of financial reports or earnings. The content is a corporate announcement about a scientific advisory board appointment, which falls under management or board information. Given the nature of the announcement about a key scientific advisory board member, the most appropriate classification is Board/Management Information (MANG). The document length is about 9,977 characters, which is consistent with a detailed announcement rather than a brief notice or report publication announcement.
2021-02-08 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the grant of stock options to directors, officers, and consultants. It details the number of options, exercise price, and terms related to resale restrictions. There is no financial data, no detailed report, no voting results, no management discussion, and no regulatory certification. The content focuses on a capital-related event (stock options granted), which is a change in the company's capital structure. The document is relatively short (4504 characters) and reads as an announcement rather than a detailed report or filing. Therefore, it fits best under Capital/Financing Update (CAP).
2021-02-05 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing a supply agreement with a global cannabis supplier and providing updates on the company's German operations and balance sheet improvements. It contains no detailed financial statements, no regulatory certifications, no voting results, no management or board changes, no earnings data, and no detailed investor presentation. The content focuses on business updates, supply agreements, and operational progress rather than financial reporting or regulatory filings. It is a typical corporate announcement about business developments and financing status, not a formal financial report or regulatory filing. Therefore, the most appropriate classification is Regulatory Filings (RNS), which serves as a fallback for miscellaneous corporate announcements that do not fit other categories.
2021-02-04 English
Material change report - English.pdf
Regulatory Filings
2021-02-02 English
Other.pdf
Regulatory Filings
2021-02-02 English
News release - English.pdf
Regulatory Filings
2021-02-02 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.